Camp4 Therapeutics CAMP 深 滬

CAMP4 Therapeutics To Host Virtual Analyst Day To Demonstrate CMP-002 Data To Treat SYNGAP1-Related Disorder

CAMP4 Therapeutics Corporation ("CAMP4") (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, will...

09-09 04:09

CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026

CAMP4 Therapeutics will host a virtual Analyst Day on September 28, 2026, to discuss SYNGAP1-related disorder and its lead candidate CMP-002, a potential disease-modifying therapy. The event will feature presentations on the clinical trial design for the first-in-human Phase 1/2 trial of CMP-002, expected to begin in Q4 2026, as well as updates on the company's early discovery pipeline. Stéphane Auvin, MD, Ph.D., a leading expert in pediatric epi...

09-08 20:05

CAMP4 to Participate in Upcoming Investor Conferences

CAMP4 Therapeutics Corporation will participate in two upcoming investor conferences: the Wells Fargo 21st Annual Healthcare Conference on September 8, 2026, in Boston, and the Cantor Global Healthcare Conference on September 9, 2026, in New York. The latter will include a fireside chat and one-on-one meetings, with a webcast available. CAMP4 focuses on developing RNA-targeting therapeutics to upregulate gene expression and treat genetic diseases...

09-01 20:05

美股大行评级 | 富国上调闪迪目标价从1400美元升至1550美元；塔吉特、Workday、应用材料等获多家大行上调目标价

今日重点评级关注：富瑞：维持ProMIS Neurosciences"买入"评级，目标价从69美元升至100美元；Benchmark：维持Cineverse"买入"评级，目标价从12美元升至14美元

08-17 13:37

Piper Sandler Reiterates Overweight on Camp4 Therapeutics, Raises Price Target to $15

Piper Sandler analyst Edward Tenthoff reiterates Camp4 Therapeutics (NASDAQ:CAMP) with a Overweight and raises the price target from $12 to $15.

08-15 00:22

Camp4 Therapeutics Q2 EPS $(0.58) Misses $(0.21) Estimate, Sales $1.779M Miss $1.897M Estimate

Camp4 Therapeutics (NASDAQ:CAMP) reported quarterly losses of $(0.58) per share which missed the analyst consensus estimate of $(0.21) by 176.19 percent. This is a 6.45 percent increase over losses of $(0.62) per share from the same period last year. The company reported quarterly sales of $1.779 mi...

08-14 04:34

CAMP4 Therapeutics Secures $50 Million Private Financing

CAMP4 Therapeutics Corporation ( ($CAMP) ) has issued an update. On August 3, 2...

08-04 19:29

CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement

08-04 11:00

CAMP4 Therapeutics Receives Clearance From Australia’s TGA And Local HREC To Initiate Phase 1/2 Clinical Trial Of CMP-002, Disease-Modifying Therapeutic For SYNGAP1-Related Disorder

Planned first-in-human clinical trial to assess a disease modifying intervention for patients with SYNGAP1-related disorder Regulatory milestone enables Company to raise up to $50 million through second closing of private placement announced September 2025 CAMBRIDGE, Mass., July 27, 2026 (GLOBE NEWS...

07-27 19:05

CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder

CAMP4 Therapeutics received clearance from Australia's TGA and HREC to initiate a Phase 1/2 clinical trial for CMP-002, a potential disease-modifying therapy for SYNGAP1-related disorder. This approval marks a significant step toward the first-in-human study for this condition, which currently has no approved treatments. The clearance also enables the company to raise up to $50 million through a second closing of its private placement, with notab...

07-27 11:00